VESPRIN
LOE ApproachingNDAORALTABLET
Approved
Sep 1957
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VESPRIN is an oral small-molecule tablet approved by the FDA in 1957 under an NDA by Bristol Myers Squibb. The specific mechanism of action, indications, and pharmacologic class are not publicly documented in available sources. This product represents a legacy pharmaceutical asset from the mid-20th century.
LOE Approaching
As a legacy product approaching loss of exclusivity with minimal current commercial data, this brand likely operates with a small, maintenance-focused team prioritizing generic transition planning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
VESPRIN currently has zero open job postings linked to the product, reflecting its late-lifecycle status. A career role on this product would involve managing decline, supporting generic transition, and maintaining compliance rather than growth-oriented activities.
Product ManagerRegulatory Affairs Specialist
Worked on VESPRIN at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.